A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT05588141 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

96

Enrollment

NIH

Sponsor class

Conditions

Brain Tumor
Cancer

Interventions

DRUG: Zotiraciclib

Sponsor

National Cancer Institute (NCI)